Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jun 23;82(8):1155–1159. doi: 10.1292/jvms.19-0559

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

©2020 The Japanese Society of Veterinary Science

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License. (CC-BY-NC-ND 4.0: https://creativecommons.org/licenses/by-nc-nd/4.0/)

PMC Copyright notice

Fig. 1. — Expression and antigenicity of recombinant vaccine candidates carrying the foot-and-mouth disease virus (FMDV) type O VP1 GH loop epitope. (A) SDS-PAGE analysis: Lane 1, total lysate of glutathione S-transferase; lane 2, soluble fraction of glutathione S-transferase (GST); lane 3, total lysate of GST-VP1; lane 4, soluble fraction of GST-VP1. (B) Western blot analysis with monoclonal antibody against type O FMDV: Lane 1, purified GST; lane 2, purified GST-VP1. (C) SDS-PAGE analysis: Lane 1, total lysate of recombinant glycoprotein fused to FMDV epitope; lane 2, soluble fraction of recombinant fused to FMDV epitope. The arrow indicates the band corresponding to the vesicular stomatitis virus glycoprotein-VP1. (D) Western blot analysis: Lane 1, total lysate of the vesicular stomatitis virus (VSV) GP-VP1 with monoclonal antibody against type O FMDV; lane 2, total lysate of the VSV GP-VP1 with monoclonal antibody against VSV glycoprotein. (E) Antigenicity of the VSV GP-VP1, GST-VP1, and GST control.